JP2020503891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503891A5 JP2020503891A5 JP2019551736A JP2019551736A JP2020503891A5 JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5 JP 2019551736 A JP2019551736 A JP 2019551736A JP 2019551736 A JP2019551736 A JP 2019551736A JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cell
- car
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017202A JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432302P | 2016-12-09 | 2016-12-09 | |
| US62/432,302 | 2016-12-09 | ||
| PCT/EP2017/082292 WO2018104562A1 (en) | 2016-12-09 | 2017-12-11 | Engineered natural killer cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Division JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503891A JP2020503891A (ja) | 2020-02-06 |
| JP2020503891A5 true JP2020503891A5 (enExample) | 2021-01-21 |
| JP7228900B2 JP7228900B2 (ja) | 2023-02-27 |
Family
ID=60937693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551736A Active JP7228900B2 (ja) | 2016-12-09 | 2017-12-11 | 操作されたナチュラルキラー細胞およびその使用 |
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10799536B2 (enExample) |
| EP (4) | EP3895712B1 (enExample) |
| JP (2) | JP7228900B2 (enExample) |
| KR (1) | KR20190114966A (enExample) |
| CN (2) | CN117305250A (enExample) |
| AU (1) | AU2017371517B2 (enExample) |
| BR (1) | BR112019011450A2 (enExample) |
| CA (1) | CA3045386A1 (enExample) |
| DK (2) | DK3581190T3 (enExample) |
| ES (3) | ES2875005T3 (enExample) |
| MX (1) | MX2019006598A (enExample) |
| WO (1) | WO2018104562A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| JP7373991B2 (ja) * | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| ES2875005T3 (es) | 2016-12-09 | 2021-11-08 | Onk Therapeutics Ltd | Células asesinas naturales manipuladas y usos de las mismas |
| CA3100341A1 (en) * | 2018-05-16 | 2019-11-21 | Research Institute Of Nationwide Children's Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
| CN119752801A (zh) * | 2018-08-01 | 2025-04-04 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
| JP2021534216A (ja) * | 2018-08-29 | 2021-12-09 | 中央研究院Academia Sinica | 癌治療のためのシクロホスファミド化合物を有するナチュラルキラー細胞の組み合わせ |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020189942A1 (ko) * | 2019-03-15 | 2020-09-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| KR102292657B1 (ko) | 2019-03-15 | 2021-08-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| CN109970869A (zh) * | 2019-04-12 | 2019-07-05 | 南京卡提医学科技有限公司 | 一种靶向人trail死亡受体的嵌合受体配体及其应用 |
| EP3958875A4 (en) * | 2019-04-25 | 2023-05-10 | Purdue Research Foundation | MANIPULATED NATURAL KILLER CELLS TARGETING PURINGERIC SIGNALING, THEIR CONSTRUCTS AND METHODS OF USE |
| JP2022554284A (ja) * | 2019-10-31 | 2022-12-28 | リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル | Ｃｄ３８ノックアウト初代および増殖ヒトｎｋ細胞の生成 |
| WO2021146521A1 (en) * | 2020-01-16 | 2021-07-22 | Acepodia Biotechnologies Ltd. | A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| WO2021209625A1 (en) * | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
| US12622959B2 (en) | 2020-08-27 | 2026-05-12 | Cellid Co., Ltd. | Coronavirus recombinant spike protein, polynucleotide encoding same, vector comprising polynucleotide, and vaccine for preventing or treating coronavirus infection, comprising vector |
| US20240141295A1 (en) | 2020-08-31 | 2024-05-02 | City Of Hope | Novel cell lines, methods of producing natural killer cells and uses thereof |
| CN114426583B (zh) * | 2020-10-29 | 2023-10-10 | 中国科学技术大学 | 用于急性髓系白血病的细胞疗法的嵌合抗原受体 |
| KR20220091426A (ko) | 2020-12-23 | 2022-06-30 | 주식회사 휴먼셀바이오 | 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물 |
| WO2022263682A1 (en) | 2021-06-18 | 2022-12-22 | Onk Therapeutics Limited | Double knockout natural killer cells |
| AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| EP4377464A4 (en) * | 2021-07-29 | 2025-07-09 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | SYNTHETIC NUCLEIC ACID ELEMENTS TO IMPROVE CAR-T CELL EFFICACY |
| WO2023044466A2 (en) * | 2021-09-18 | 2023-03-23 | Sunnybay Biotech, Inc. | Herv-k antibody, cell, vaccine, and drug therapeutics |
| WO2023102201A2 (en) * | 2021-12-03 | 2023-06-08 | University Of Utah Research Foundation | High selective cd229 antigen binding domains and methods of use |
| CN120051297A (zh) | 2022-06-30 | 2025-05-27 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法 |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| JP2025536042A (ja) | 2022-11-10 | 2025-10-30 | オーエヌケイ セラピューティクス リミテッド | 免疫調節薬を用いた併用療法 |
| WO2024238387A1 (en) * | 2023-05-12 | 2024-11-21 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025073908A1 (en) | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| WO2025146467A1 (en) | 2024-01-04 | 2025-07-10 | Onk Therapeutics Limited | Targeted il-15 construct delivery |
| KR20250118299A (ko) | 2024-01-29 | 2025-08-06 | 인하대학교 산학협력단 | 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법 |
| WO2025184169A1 (en) * | 2024-02-26 | 2025-09-04 | The Regents Of The University Of California | Oleate-mediated enhancement of human natural killer cell function |
| WO2025239292A1 (ja) * | 2024-05-15 | 2025-11-20 | 株式会社Cured | 改変ナチュラルキラー細胞株 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2516128A1 (en) * | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| AU2007302448C1 (en) | 2006-09-26 | 2019-02-14 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| WO2008049098A2 (en) | 2006-10-19 | 2008-04-24 | Merck & Co., Inc. | ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1 |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| EP3241897B1 (en) | 2013-03-07 | 2018-10-03 | Baylor College of Medicine | Targeting cd138 in cancer |
| AU2015216875B2 (en) * | 2014-02-14 | 2021-02-25 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US10934346B2 (en) * | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| HRP20191400T1 (hr) | 2014-12-24 | 2019-11-15 | Aadigen Llc | Peptidi i nanočestice za unutarstaničnu isporuku molekula |
| EP3240551A4 (en) | 2014-12-31 | 2018-08-08 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| JP7269733B2 (ja) | 2015-06-12 | 2023-05-09 | レンティジェン・テクノロジー・インコーポレイテッド | 操作されたｔ細胞を用いて癌を処置するための方法 |
| TW202444897A (zh) | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| CN116064401A (zh) | 2015-07-29 | 2023-05-05 | 昂克医疗有限公司 | 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| ES2875005T3 (es) * | 2016-12-09 | 2021-11-08 | Onk Therapeutics Ltd | Células asesinas naturales manipuladas y usos de las mismas |
| WO2018104554A1 (en) | 2016-12-09 | 2018-06-14 | Onkimmune Limited | Improved nk-based cell therapy |
| WO2019201629A1 (en) | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with antibodies in cancer therapy |
-
2017
- 2017-12-11 ES ES19176141T patent/ES2875005T3/es active Active
- 2017-12-11 EP EP21160170.3A patent/EP3895712B1/en active Active
- 2017-12-11 CN CN202311063691.5A patent/CN117305250A/zh active Pending
- 2017-12-11 KR KR1020197019363A patent/KR20190114966A/ko not_active Ceased
- 2017-12-11 EP EP17825774.7A patent/EP3454871B1/en active Active
- 2017-12-11 US US15/837,576 patent/US10799536B2/en active Active
- 2017-12-11 CA CA3045386A patent/CA3045386A1/en active Pending
- 2017-12-11 WO PCT/EP2017/082292 patent/WO2018104562A1/en not_active Ceased
- 2017-12-11 DK DK19176141.0T patent/DK3581190T3/da active
- 2017-12-11 DK DK17825774.7T patent/DK3454871T3/da active
- 2017-12-11 BR BR112019011450-5A patent/BR112019011450A2/pt not_active IP Right Cessation
- 2017-12-11 EP EP19176141.0A patent/EP3581190B1/en active Active
- 2017-12-11 CN CN201780085686.0A patent/CN110248669B/zh active Active
- 2017-12-11 ES ES17825774T patent/ES2746856T3/es active Active
- 2017-12-11 ES ES21160170T patent/ES2926397T3/es active Active
- 2017-12-11 JP JP2019551736A patent/JP7228900B2/ja active Active
- 2017-12-11 MX MX2019006598A patent/MX2019006598A/es unknown
- 2017-12-11 AU AU2017371517A patent/AU2017371517B2/en active Active
- 2017-12-11 EP EP22179362.3A patent/EP4104841A1/en active Pending
-
2020
- 2020-08-31 US US17/008,506 patent/US12534536B2/en active Active
-
2023
- 2023-02-07 JP JP2023017202A patent/JP2023052980A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| PH12018501778A1 (en) | Antibodies to tigit | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| JP2012254092A5 (enExample) | ||
| JP2014505463A5 (enExample) | ||
| JP2020526214A5 (enExample) | ||
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| JP2017518258A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| JP2017513478A5 (enExample) | ||
| WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
| JP2018524326A5 (enExample) | ||
| JP2017537972A5 (enExample) | ||
| JP2018509163A5 (enExample) | ||
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| JP2017508466A5 (enExample) | ||
| JP2015527070A5 (enExample) |